Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004516614 | SCV005021952 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-12-08 | criteria provided, single submitter | clinical testing | The c.1230_1231delTCinsAA variant (also known as p.L411I), located in coding exon 6 of the BLM gene, results from an in-frame deletion of TC and insertion of AA at nucleotide positions 1230 to 1231. This results in the substitution of the leucine residue for an isoleucine residue at codon 411, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be neutral by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |